



SARS-COV-2 Neutralizing Antibody

Catalog No. A19215 Category Primary antibody

Description SARS-COV-2 Neutralizing Antibody is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from

human 293 cells (HEK293). This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2 with an IC50 of 0.496 $\,\mu$ g/mL using SARS-CoV-2 Inhibitor Screening

Kit (Cat. No. RK04149).

Product information

SourceHumanAffinity purification byProtein AIsotypeHuman IgG1Concentration1 mg/mL

Purity >95% by SDS-PAGE.


Endotoxin < 0.1 EU/µg of the protein by LAL method.

Formulation Lyophilized from a 0.22 µm filtered solution of PBS, pH 7.2, with 10% Trehalose.

Storage Store the lyophilized protein at -20 °C to -80 °C for long term.


Avoid repeated freeze/thaw cycles.

Binding Activity



Immobilized SARS-CoV-2 S1 protein, His Tag (Cat. No. RP01262) at 1 μ g/mL (100 μ L/well) can bind Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1 (Cat. No. A19215) with a linear range of 0.078-5 ng/mL

Inhibition Activity



Serial dilutions of Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1 (Cat.No. A19215) was detected by SARS-CoV-2 Inhibitor screening Kit (Cat.No. RK04149) with a half maximal inhibitory concentration (IC50) of 0.496ug/mL.

Nous contacter

Service client - commande : commande@ozyme.fr

Service technique:

Réactifs: 01 34 60 60 24 - tech@ozyme.fr

Instrumentation: 01 30 85 92 88 - instrum@ozyme.fr

